Compare Quest Diagnostics Inc (DGX) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Lennar Corporation — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Lennar Corporation trades at $83.75 (market cap $20.12B). The key difference: Quest Diagnostics Inc and Lennar Corporation are close in size by market cap, and Lennar Corporation pays the higher dividend (2.39%). Which is the better fit depends on your goals.
| DGX | LEN | |
|---|---|---|
Market Cap | $22.80B | $20.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $142.40 |
52-Week Low | $166.42 | $82.30 |
Enterprise Value | $28.82B | $24.00B |
Dividend Yield | 1.67% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Lennar Corporation (LEN) trades at $82.84, down 1.7% on the day, with technical indicators showing bearish momentum despite oversold RSI conditions. The stock faces fundamental pressure from declining revenue and net income margins, which fell to 6.07% in 2025 from 13.7% in 2022. Recent earnings misses and housing affordability challenges create headwinds, though analyst consensus remains positive with a $84.38 price target.
LEN presents a value opportunity with attractive valuation multiples (P/E 12.98, P/B 0.92) but faces execution risks amid declining profitability. The housing market's sensitivity to mortgage rates and competitive pressures require careful monitoring. Upside potential exists if operational improvements and housing policy support materialize, making this suitable for patient investors comfortable with cyclical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
